| Outcome Measures: |
Primary: Change to be observed with canagliflozin on myocardial dietary fatty acid uptake, will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid (\[18F\]-FTHA) with sequential dynamic. PET/CT scanning., 3 months|Change to be observed with canagliflozin on whole-body partitioning., will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid (\[18F\]-FTHA, with static PET/CT scanning, 3 months | Secondary: myocardial and liver NEFA uptake, using PET with \[11C\]-palmitate, 3 months|NEFA oxidative rate, using PET with \[11C\]-acetate, 3 months|plasma NEFA turnover, using i.v. infusion of \[U-13C\]-palmitate, 1 year | Other: Insulin sensitivity, will be determined using the HOMA-IR (based on fasting insulin and glucose levels), 1 year|Insulin secretion rate, will be assessed using deconvolution of plasma C-peptide with standard Cpeptide kinetic parameters, 1 year|β-cell function, will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin, 1 year|hormonal response, will be determined using a multiplex assay system, 1 year|Biomarkers, Assays will be performed using the BIOPLEX, 1 year|body composition, DXA, 3 months
|
